Acute Effect of Aliskiren on Smoking-Induced Endothelial Dysfunction in Smoker

• Main Authors: Haruhito Adam Uchida (Author), Hatsuzo Uchida (Author), Jun Wada (Author)
• Format: Book
• Published: Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications, 2014-10-27.
• Subjects: Short Communication
• Online Access: Connect to this object online.

<p><strong>Background: </strong>We aimed to examine the acute effect of aliskiren on smoking-induced endothelial dysfunction in smoker.</p><p><strong>Methods: </strong>Nineteen male smokers were enrolled. After all participants smoked a cigarette, their endothelial function was assessed with brachial artery flow mediated dilation (FMD). An hour after the administration of aliskiren, they smoked again, their FMD was assessed again. A month later, all measurements were performed again without the administration of aliskiren as a control. Blood pressure, plasma renin activity, and serum interleukin-6 concentration were also examined at the same time of FMD measurement.</p><p><strong>Results:</strong> A cigarette smoking led to an acute endothelial dysfunction (6.5 ± 1.7% to 3.4 ± 1.0 %, P = 0.02). Aliskiren administration significantly suppressed blood pressure and plasma renin activity, furthermore, improved FMD (6.7 ± 0.5% to 8.1 ± 0.8 %, P = 0.03). Aliskiren significantly reduced serum interleukin-6 concentration, but not in control.</p><p><strong>Conclusion:</strong> Aliskiren has a beneficial effect on smoking-induced acute endothelial dysfunction.</p>